ROR1
Assets acting on this target.
- Class
- Antibody-drug conjugate targeting ROR1
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; cited page names the drug and the target); source: https://www.merck.com/research/pipeline/
Related mechanisms
ROR1 drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Zilovertamab vedotin | Merck & Co. | antibody-drug conjugate | Phase 2/3 | Phase 2/3 in Diffuse Large B-Cell Lymphoma |
| IM-1021 | Immunome, Inc. | antibody-drug conjugate | Phase 1 | Not recorded |